

Cardiac Arrhythmias

defined as a disturbance of the electrical rhythm of the heart.

heart rate of more than 100/min is called tachycardia.

heart rate of less than 60/min is called bradycardia.

* Types

There are five main types of arrhythmias, described by speed of heart rate they cause, and where they begin in the heart.

1. Tachycardia

this fast heart rhythm causes a heart rate of more than 100 beats per minute.

it is usually due to an rise in sympathetic activity.

Sinus tachycardia does not require treatment.

But in some cases β -blockers, CCB, Ivabradine are prescribed.

2. Bradycardia

this slow heart rhythm causes a heart rate of less than 60 beats per min.

if bradycardia is asymptomatic, then no treatment is required.

Symptomatic bradycardia occurs during MI and can be treated with atropine (0.6 - 1.2 mg).

Patient with persistent symptoms of sinus bradycardia should be considered for pacemaker implantation.

3. Premature heartbeat

a premature or extra heart is common, usually harmless type of arrhythmia that typically does not cause symptoms.

People who experience an occasional extra heart beat do not need treatment.

4. Supraventricular Tachycardia

from above the ventricles

↳ fast heart rate

∴ comes from atria

* most common cause of the SVT is when electrical signal re-entering atria from ventricles once signal is back in atria it travels back to AV node causing another ventricular contraction



cause self-perpetuating electrical loop (without an end point)


* SVT causes narrow complex tachycardia

↳ duration of QRS complex is < 0.12 sec (3 sq)

↳ 4 differentials of NCT
sinus tach, SVT, atrial fibrillation, atrial flutter

Types of SVT depending on the source of electrical signals.


a. Atrial fibrillation :



Commonly, AF is classified as paroxysmal, persistent or permanent.

b. Atrial flutter :


300 bpm, sawtooth pattern
 QRS regular.



2 atrial contraction : 1 ventricular contraction

c. Paroxysmal supraventricular tachycardia

It describes a situation in which SVT occurs in same patient over time in between which there are period of normal rhythms.




Rapid, regular heartbeat that begins & ends suddenly

d. Atrioventricular Re-entrant tachycardia (Wolf-Parkinson-White)

Accessory pathway, refers to an additional electrical pathway betⁿ atria and ventricles.

Additional pathway from ventricles



5. Ventricular arrhythmias:-

Tachycardias that begin in lower chambers of the heart.

a. Ventricular tachycardia:


Rapid, regular heartb that can last for just few sec.
This increases risk of

ventricular fibrillation.

IV amiodarone may be given; IV lidocaine for left V. B-blockers are also effective.

b) Ventricular fibrillation:


Rapid, irregular hb that causes ventricles to quiver ineffectively instead of pumping blood.
This can lead to cardiac arrest.

0 - regularity 

No P wave no PR interval No QRS complex

c) Torsades de pointes

Torsade de pointes is a peculiar form of very rapid ventricular rhythm.



Treatment - Magnesium, withdrawal of offending agent & maintain electrolytic balance

Drugs & Toxin causing TdP:

- Procainamide, Quinidine (anti-arrhythmic)
- Erythromycin, ofloxacin (anti-biotic)
- Fluoxetine, "Haloperidol", Lithium
(anti-depp) (anti-psyco) (bipolar disorder)
- Tricycline anti depressant.
- Organophosphate insectides.

Pathogenesis

Cardiac arrhythmia usually occur as result of pathology affecting the conduction system of heart.

Cardiac cycle is normally initiated by an electrical discharge from the SA node. Atria and ventricle then are activated sequentially, as electrical depolarisation passes through specialized conducting tissues.

Three major underlying mechanisms have been identified:

- Increased automaticity
- Re-entry
- Triggered activity

a. Increased Automaticity:

↑ed automaticity occur in cells that normally have spontaneous diastolic depolarization i.e., — the sinus and AV node and His-Purkinje sys.

↳ This automatic behaviour may occur in sites that lack spontaneous pacemaker activity

Eg: depolarization of ventricular cells (eg by ischemia) may produce

Such "abnormal" automaticity.

b. Re-entry
Tachycardia is initiated by an ectopic (premature) beat and sustained by a re-entry circuit.

Re-entry occurs when there are two alternative pathways with diff. conducting properties.

c. Triggered activity
In some conditions, a normal cardiac action potential may be interrupted or followed by an abnormal depolarization.

If this abnormal depolarization reaches threshold, it may, in turn give rise to secondary upstroke and create abnormal rhythms.

(Arrhythmias may be supraventricular (sinus, atrial or junctional) or ventricular in origin.) ✓

Bradycardia may be due to reduced automaticity of the SA node or abnormalities of conduction through AV node.

If the sinus node becomes slow, only part of the conducting sys may play the role of pacemaker. This is known as escape rhythm and may arise from AV node or His bundle (junctional^{hythm}) or in ventricle (idioventricular rhythm).

Anti- Arrhythmic agents

Class I

Na^+ channel blockers
(membrane stabilizing agents)

IA

moderately decrease phase 0 depolarⁿ
Quinidine
Procainamide
Disopyramide

IB

minimal effect on phase 0 depⁿ
Lidocaine
Mexiletine

IC

marked decrease in phase 0 depⁿ
Propafenone
Flecainide

Class II

β -adrenergic blockers
(Anti-adrenergic agents)

Propranolol
Esmolol

Class III

drugs that prolong duration
of action potential

Amiodarone

Dronedarone

Sotalol

Dofetilide

Ibutilide

Class IV

Calcium channel blockers

Verapamil

Diltiazem

Drugs for Paroxysmal supraventricular tachycardia
(PSVT)

Adenosine

Digoxin

Atropin

Ivabradine

Pharmacology of Class I:

The primary action of drugs in this class is to limit the conductance of Na^+ across the membrane — a local anesthetic action.

Class Ia

Drugs — Quinidine
Procainamide
Disopyramide

*Quinidine :

(a) Mechanism of action :

It blocks Na^+ channels in the open state \longrightarrow decreases automaticity
decreases excitability
decreases conduction
decreases rate of phase 0 depolarization

It blocks K^+ channels \longrightarrow increases duration of action potential
blocks re-entry of impulse

ECG : It prolongs QRS complex and QT interval.

(b) Pharmacokinetics

Absorbed in GI tract

Bound to plasma proteins

Metabolized in liver

Excreted 20% unchanged in urine

(c) Adverse effects

- Diarrhoea
- Fall in BP
- Torsades de pointes
- Hepatitis & fever (rare)
- Produce syndrome - 'Cinchonism'

↓ causes
deafness, headache, blurring of vision, confusion, psychoses.

(d) Uses

It has a broad spectrum of anti-arrhythmic activity.

Useful in maintaining normal sinus rhythm

↓
in atrial fibrillation / atrial flutter
occasionally in ventricular tachycardia

(e) Dose


100 - 200mg TDS

Class 1b

Drugs — Lidocaine
Mexiletine

* Lidocaine :

(a) Mechanism of action



(b) Pharmacokinetics

Orally - Inactive $t_{1/2}$ - 8 min
 IV - last for 10-20 min ;
 Metabolized - Liver (blood) ;
 Excreted - urine

(c) Adverse effect

- Main toxicity is related to neurological effect
 Drowsiness
 Nausea
 blurred vision
- Cardiac depression } high dose
- hypotension }

(d) uses

It is safe if given by slow IV inj.

Given in MI to prevent ventricular fibrillation

Generally use in emergency treatment of
 • ventricular tachycardia.

Not used in atrial arrhythmia.

(e) Dose

- 20-40 mg IV every 10-20 min
- 1-3 mg/min IV

Class 1c

Drugs — Propafenone
Flecainide

(a) Mechanism of action

Propafenone



Slows influx of Na^+ in cardiac cells



This causes depressed impulse transmission



Has very good effect on
His Purkinje



helps to decrease WPW syndrome

(b) Pharmacokinetics

Absorbed - orally

$t_{1/2}$ - varies

Metabolism - first pass

Excreted - through urine

(c) Adverse effects

Constipation

Vomiting

Bradycardia -

Bitter taste (metallic)

bronchospasm

Asthma

Blurred vision

Increase risk of sudden death

Nausea

(d) Uses

Mainly used to maintain sinus rhythm in patient having AF

used for supraventricular tachycardia
also for ventricular arrhythmias.

(e)

Dose

150 - 300

mg

TDS